NASDAQ$LYRA
Lyra Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Lyra Therapeutics reported a net loss of $22.5 million for Q1 2024, compared to a net loss of $16.3 million for the same period in 2023. Cash, cash equivalents, and short-term investments totaled $87.1 million as of March 31, 2024. The company anticipates its cash balance will fund operations into the first quarter of 2025.
- Results from the ENLIGHTEN 1 pivotal Phase 3 clinical trial of LYR-210 are expected in May 2024.
- Enrollment in ENLIGHTEN 2 is expected to be completed in the second half of 2024.
- Results from the ENLIGHTEN 1 52-week extension study are expected in Q4 2024.
- An end-of-Phase 2 meeting for LYR-220 with the FDA is anticipated in the second half of 2024.
Headline financials
Revenue & EPS history
Lyra · Revenue · Quarterly
$532K
Revenue by segment
Lyra · $410K total across 1 segment · Q1 2023
- Collaboration revenue$410K—100.0%
Forward guidance
Lyra Therapeutics anticipates that its cash, cash equivalents and short-term investment balance is sufficient to fund its operating expenses and capital expenditures into the first quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-1.6%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-1.7%
Avg return
30 days after
29%
7 / 24 earnings
Positive
+11.0%
Q1 2024
Best reaction
-25.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.0% | +0.1% | +52.2% | |
| Q3 2025 | -1.0% | -5.9% | -6.3% | |
| Q2 2025 | +9.5% | +8.3% | -6.8% | |
| Q1 2025 | -6.3% | -17.3% | +102.9% | |
| Q4 2024 | -4.1% | -14.8% | -39.2% | |
| Q3 2024 | -25.4% | -35.8% | -23.8% | |
| Q2 2024 | -3.3% | +4.0% | -6.6% | |
| Q1 2024 | +11.0% | -14.8% | -93.0% | |
| Q4 2023 | +2.8% | +1.0% | -14.5% | |
| Q3 2023 | +0.0% | +2.4% | +33.4% | |
| Q2 2023 | +5.4% | +13.8% | +20.8% | |
| Q1 2023 | -6.8% | -2.1% | +3.6% | |
| Q4 2022 | +6.1% | +13.8% | +22.4% | |
| Q3 2022 | -17.9% | -20.3% | -35.8% | |
| Q2 2022 | -1.7% | +0.6% | -5.2% | |
| Q1 2022 | +7.1% | +7.7% | +18.1% | |
| Q4 2021 | -4.0% | -5.8% | +22.8% | |
| Q3 2021 | -1.0% | -0.4% | -32.9% | |
| Q2 2021 | -3.9% | -0.4% | +17.6% | |
| Q1 2021 | -1.0% | -5.6% | +11.9% | |
| Q4 2020 | -4.8% | -2.2% | -20.9% | |
| Q3 2020 | +1.0% | -1.8% | -13.3% | |
| Q2 2020 | -0.9% | +0.9% | -17.8% | |
| Q1 2020 | -0.5% | +0.1% | -31.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro